68Ga-ATH001

**68Ga-ATH001** is an investigational **gallium-68 PET radiotracer** being developed by **Antaros Medical** and its tracer-focused affiliate **Antaros Tracer** for **non-invasive imaging of fibrogenesis**. The tracer is described as a **PDGFRβ-targeting** probe intended to detect and quantify **active fibrotic disease** in tissues, with particular development emphasis on liver and gastrointestinal fibrotic disorders. Clinical materials describe first-in-human microdose PET studies comparing tracer binding in healthy volunteers versus patients with **metabolic dysfunction-associated steatohepatitis**, **primary sclerosing cholangitis**, and **fibrostenotic Crohn's disease**. Mechanistically, it functions as a **targeted diagnostic radiopharmaceutical** rather than a therapeutic agent: a peptide-based ligand linked through DOTA and labeled with gallium-68 binds **platelet-derived growth factor receptor beta**, enabling PET visualization of sites of ongoing fibrogenesis.

Other names

gallium Ga 68 DOTA-Cys-ATH001